GlassScriptPhysician profile
Sarah I Little
NPI 1972512580
$562.76
in general payments reported to CMS, 2019-2025
15 companies · $73.39 in 2025
The $73.39 reported for 2025 was less than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $61.64 · 2020: $78.62 · 2021: $128 · 2022: $153 · 2023: $37.28 · 2024: $30.00 · 2025: $73.39.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $141.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $140.67 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $112.11 | 2021-2023 | Freestyle Libre 3 |
| Novartis Pharmaceuticals Corporation | $65.03 | 2019-2020 | |
| Abbvie INC. | $61.54 | 2022-2025 | |
| Pfizer INC. | $61.21 | 2019-2025 | |
| Dexcom, INC. | $52.66 | 2023-2025 | Dexcom G6 Transmitter |
| Lundbeck LLC | $49.73 | 2020-2021 | |
| Glaxosmithkline, LLC. | $37.94 | 2021 | |
| Jazz Pharmaceuticals INC. | $21.63 | 2022 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $16.58 | 2022 | |
| Biohaven Pharmaceuticals, INC. | $16.10 | 2021 | |
| Bayer Healthcare Pharmaceuticals INC. | $14.69 | 2022 | |
| Teva Pharmaceuticals USA, INC. | $14.62 | 2022 | |
| Boston Scientific Corporation | $14.16 | 2022 | |
| Janssen Pharmaceuticals, INC | $12.94 | 2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $11.82 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sarah Little listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.